8-K: STAAR Surgical Reports Strong Q4 and Fiscal Year 2023 Results, Driven by ICL Sales Growth

STAAR Surgical reported a 19% increase in net sales for the fourth quarter of 2023, driven by a 22% surge in ICL sales, and affirms its 2024 sales outlook.

Summary

• STAAR Surgical Company announced its financial results for the fourth quarter and fiscal year ended December 29, 2023.
• Net sales for the fourth quarter increased by 19% to $76.3 million, compared to $64.0 million in the prior year quarter.
• ICL sales for the fourth quarter grew by 22% to $74.6 million, with a 19% increase in ICL unit sales.
• The company's gross margin for the fourth quarter was 79.6%, up from 77.7% in the prior year quarter.
• Net income for the fourth quarter was $7.8 million, or $0.16 per diluted share, compared to $6.8 million, or $0.14 per diluted share, in the prior year quarter.
• For the full fiscal year 2023, net sales increased by 13% to $322.4 million, compared to $284.4 million in the prior year.
• ICL sales for the full year grew by 18% to $319.4 million, with a 19% increase in ICL unit sales.
• The company's gross margin for the full year was 78.4%, slightly down from 78.5% in the prior year.
• Net income for the full year was $21.3 million, or $0.43 per diluted share, compared to $39.7 million, or $0.80 per diluted share, in the prior year.
• STAAR Surgical is affirming its fiscal year 2024 net sales outlook of $335 million to $340 million.
• The company ended the year with $232.4 million in cash, cash equivalents, and investments available for sale.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales growth, improved profitability in Q4, and a positive outlook for 2024. The company's focus on innovation and strategic investments further contribute to the positive sentiment. However, the decrease in full year net income and increase in operating expenses temper the overall sentiment slightly.

Positives

• The company experienced strong sales growth in the fourth quarter, consistent with preliminary announcements.
• Profitability was driven by strength in the APAC region and sequential growth in EMEA.
• Every large market delivered positive sales growth for fiscal year 2023.
• ICL unit growth exceeded refractive industry growth by over 25 points for the third consecutive year.
• The company has a healthy gross margin and no debt.
• The company has a record $232 million of cash, cash equivalents and investments on the balance sheet.
• The company is strategically investing in growth opportunities and enhancing the surgeon experience.
• The company is seeing increasing interest in its lens-based technology.
• Operating income for the fourth quarter of 2023 was $10.4 million, a significant increase from $1.0 million in the prior year quarter.
• The company is affirming its fiscal year 2024 net sales outlook of $335 million to $340 million.

Negatives

• Net income for the full year 2023 decreased to $21.3 million from $39.7 million in the prior year.
• Earnings per share for the full year 2023 decreased to $0.43 from $0.80 in the prior year.
• Operating expenses for fiscal year 2023 increased by 25% due to higher compensation-related expenses and marketing activities.
• Other Products sales decreased 43% in Q4 2023 and 80% for the full year 2023.
• Gross profit margin for fiscal year 2023 decreased slightly to 78.4% from 78.5% in the prior year.

Risks

• The company's future performance is subject to global economic conditions.
• Regulatory agencies have the discretion to approve or reject products.
• The company is substantially dependent on demand from Asia.
• The willingness of surgeons and patients to adopt new products and procedures is a risk.
• International conflicts and trade disputes could impact the company's performance.
• The company's forward-looking statements are subject to numerous risks and uncertainties.

Future Outlook

The company expects net sales of $335 million to $340 million for fiscal year 2024 and adjusted EBITDA of approximately $36 million, or $0.70 per diluted share. This outlook includes ICL sales growth of approximately 7% in APAC, 10% in the Americas, and EMEA sales consistent with fiscal year 2023.

Management Comments

• Tom Frinzi, President and CEO of STAAR Surgical, stated that the company generated strong sales growth in the fourth quarter and profitability, driven by strength in APAC and sequential growth in EMEA.
• Mr. Frinzi also noted that every large market delivered positive sales growth for fiscal 2023.
• Mr. Frinzi mentioned that ICL unit growth exceeded refractive industry growth by over 25 points for the third year in a row.
• Mr. Frinzi stated that the company is affirming its fiscal 2024 net sales outlook of $335 million to $340 million.
• Mr. Frinzi highlighted the company's healthy margins, no debt, and record cash balance, which will allow them to strategically invest in growth opportunities.

Industry Context

The announcement reflects a positive trend in the refractive surgery market, particularly for ICL procedures. STAAR Surgical's growth is outpacing the overall market, indicating a strong competitive position and increasing adoption of their EVO ICL technology. The company's focus on innovation and surgeon experience aligns with industry trends towards advanced and patient-centric solutions.

Comparison to Industry Standards

• STAAR Surgical's ICL unit growth exceeded the refractive industry growth by over 25 points for the third consecutive year, indicating a strong market position compared to competitors like Johnson & Johnson Vision, Alcon, and Bausch + Lomb, who offer alternative refractive solutions.
• The company's 22% global ICL sales growth in the quarter, including 30% growth in China and 18% in EMEA, demonstrates a strong performance in key international markets, outperforming many competitors who may have a more diversified product portfolio.
• While specific financial details for direct competitors are not provided in this document, STAAR's focus on ICL technology and its strong growth in this segment suggests a competitive advantage in the premium refractive lens market.
• The company's gross margin of 79.6% in Q4 2023 is a strong indicator of profitability and efficiency, which is a key metric when comparing to other medical device companies.

Stakeholder Impact

• Shareholders will likely react positively to the strong Q4 results and positive outlook for 2024.
• Employees may benefit from the company's growth and strategic investments.
• Surgeons will benefit from the company's focus on enhancing the surgeon experience.
• Patients will benefit from the company's innovative lens-based technology.

Next Steps

• The company will host a conference call and webcast on February 26, 2024, to discuss its financial results and operational progress.
• The company plans to share more about its progress, partnerships, and innovation investments in the coming weeks and at the ASCRS meeting in Boston.

Key Dates

Keywords

ICL, Implantable Collamer Lens, EVO ICL, Ophthalmology, Refractive Surgery, Net Sales, Gross Margin, Net Income, APAC, EMEA, China, Financial Results, Adjusted EBITDA